Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Jagadeswara Rao EarlaJieni LiGeorge J HuttonMichael L JohnsonRajender R AparasuPublished in: Pharmacotherapy (2023)
Teriflunomide and DMF were associated with poorer adherence trajectories than FIN. More research is needed to evaluate the clinical implications of these adherence trajectories of oral DMAs to optimize the management of MS.